Neuron23 Closes $100 Million Series C Financing Round, Nominates Clinical Candidate for Parkinson's Disease

SoftBank Vision Fund 2 leads round with participation from all existing investors Company expects to bring LRRK2 candidate into the clinic for Parkinson's disease by end of 2022 Valentin Barsan, M.D., and Jim Scopa join Neuron23 board of directors ... Biopharmaceuticals, Neurology, Venture Capital Neuron23, precision medicine, Parkinson's disease
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news